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Abstract
Mandatory folic acid fortification in the United States corresponded with a decline in the 
prevalence of spina bifida (SB). The aim of this study was to describe the epidemiologic 
characteristics of isolated versus non-isolated SB cases in both pre- and post-fortification periods. 
SB cases in the Slone Epidemiology Center Birth Defects Study from 1976 to 2011 without 
chromosomal anomalies and syndromes were included. A maternal interview, conducted within 6 
months of delivery, collected information on demographics, reproductive history, diet, and 
supplement use. Daily folic acid intake in the periconceptional period was calculated using both 
dietary and supplement information and categorized as low intake (<400 μg/day) or high intake 
(≥400 μg/day). SB cases (n=1170) were classified as isolated (80.4%) or non-isolated (19.1%). 
Non-isolated cases were further divided into subgroups based on accompanying major 
malformations (midline, renal, genital, heart, laterality). Compared to non-isolated cases, isolated 
cases were more likely to be white, non-Hispanic and have more than 12 years of education. Cases 
in the renal, genital, and heart subgroups had the lowest proportions of mothers with a high folic 
acid intake. The change from pre- to post-fortification was associated with a decrease in the 
proportion of isolated cases from 83% to 72%, though in both periods isolated cases were more 
likely to be female and their mothers were more likely to have high folic acid intake. These 
findings highlight the importance of separating isolated and non-isolated cases in etiologic 
research of SB.
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Spina bifida (SB) is a type of neural tube defect (NTD) resulting from incomplete closure of 
the neural tube during embryonic development. SB frequently results in paralysis below the 
level of the lesion and is associated with long-term physical and cognitive disabilities 
[Hetherington et al., 2006; Jenkinson et al., 2011]. The prevalence of SB in the United States 
from 2004 to 2006 was 3.5 per 10,000 live births, affecting an estimated 1,460 infants 
annually [Parker et al., 2010]. One-year survival of infants with SB is estimated to be 90.8% 
[Shin et al., 2012].
Established risk factors for SB include family history, pre-gestational diabetes [Correa et al., 
2008], maternal obesity [Shaw et al., 1996; Watkins et al., 2003; Waller et al., 2007], and 
insufficient intake of folic acid [Medical Research Council Vitamin Study Research Group, 
1991; Czeizel and Dudas, 1992; Werler et al., 1993]. Studies have investigated several other 
environmental and dietary exposures as potential risk factors, but findings have been less 
definitive, leaving the majority of SB cases with unknown causes. It has long been observed 
that risk factors for neural tube defects differ according to whether the defect is isolated or 
accompanied by other malformations (“non-isolated”) [Holmes et al., 1976; Khoury et al., 
1982], suggesting that isolated SB and non-isolated SB are etiologically heterogeneous. 
Frequently, epidemiologic studies of risk factors for SB do not distinguish between such 
classifications, potentially hindering identification of risk factors.
Most of the literature on epidemiologic characteristics of isolated versus non-isolated cases 
of SB precedes the era of folic acid fortification, which was mandated in the United States in 
1998. The transition from pre-fortification to fortification was associated with a 31% 
decrease in the prevalence of SB in the immediate post-fortification period [Williams et al., 
2002]. The prevalence of SB has continued to decrease, but the decline has been more 
gradual [Boulet et al., 2008]. Further research revealed a significant decline between 1992 
and 2009 in the prevalence of isolated NTDs, but not non-isolated NTDs [Collins et al., 
2011]. The evidence suggesting that folic acid may be more effective in reducing the 
occurrence of isolated SB than non-isolated SB raises the possibility that the characteristics 
of cases have changed over time [Yen et al., 1992]. The objective of this study is to describe 
characteristics of isolated SB and SB accompanied by other major malformations in a case 
group that spans both pre- and post-fortification time periods.
MATERIALS AND METHODS
The Slone Epidemiology Center Birth Defects Study (BDS)is an on-going case–control 
study in the United States and Canada that began in 1976. Cases of birth defects are 
ascertained from birth hospitals or tertiary care centers in Boston, MA (1976+); 
Philadelphia, PA (1976+); San Diego, CA (2001+); Toronto, Canada (1976–2005); selected 
counties in Iowa (1983–1985); and from birth defects registries in Massachusetts (1999+) 
and parts of New York State (2004+). Cases include primarily livebirths;though fetal deaths 
and elective terminations were eligible for inclusion beginning in 1990, ascertainment of 
these cases has not been routine.
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A maternal interview is conducted by a trained nurse interviewer within 6 months of 
delivery. The interview captures information on demographics, pregnancy history, 
medication use, supplement use, and family history of birth defects.
CASE CLASSIFICATION
The present study includes SB cases ascertained between 1976 and 2011. All cases of SB 
were classified by a clinical geneticist (LD). Cases were classified as isolated, non-isolated, 
or unknown. Isolated cases were those with no other major malformations, but may have 
had minor malformations or deformations (e.g., heart murmurs, patent foramen ovale, patent 
ductus arteriosus, skin tags, tethered cord, tongue-tie, hip clicks, type B (minimus) post-axial 
polydactyly, rockerbottom feet, hemangiomas, inguinal hernias, and umbilical hernias), or 
anomalies considered to be secondary to SB (other NTDs, hydrocephaly, clubfoot, and 
congenital hip dislocation). Non-isolated cases were those with at least one other major non-
NTD malformation. Unknown cases had confirmed SB but lacked sufficient detail on other 
malformations to warrant classification as either isolated or non-isolated. Cases with a 
chromosomal anomaly, amniotic band syndrome, a body wall defect, conjoined twins, or 
selected recognized syndromes (Holt-Oram, Aicardi, Fryns, Meckel-Gruber, Currarino triad, 
and Seckel) were excluded. Cases without a confirmed medical record diagnosis of SB were 
also excluded. Information on the source of case confirmation was available beginning in 
1988; subsequently 97.4% of cases were confirmed on the basis of information in the 
medical record.
NON-ISOLATED DEFECT SUBGROUPS
Non-isolated cases were further classified into subgroups based on the type of other major 
defects present: midline defects, renal/urinary defects, genital defects, heart defects, and 
laterality defects. Midline defects included conotruncal heart defects, oral clefts, brain 
reduction defects, omphalocele, hypospadias, and diaphragmatic hernia [Khoury et al., 
1989]. Infants with congenital hydrocephalus were not considered as having a non-isolated 
midline defect due to the likelihood that it is secondary to SB. Renal/urinary defects 
included renal agenesis, absent kidney, and polycystic kidney. Hydronephrosis and vesico-
ureter reflux were not considered major renal malformations. Genital defects included 
undescended testes at >37 weeks’ gestation, ambiguous genitalia, and hypospadias. Heart 
defects included ventricular septal defects, conotruncal heart defects, and coarctation of the 
aorta. Laterality defects included polysplenia and dextrocardia. Due to the possibility of a 
case having multiple major malformations, subgroup categories are not mutually exclusive.
COVARIATES
Data on demographics and reproductive history were collected through the maternal 
interview. Prior to 1983, women who reported Hispanic ethnicity were included in the 
“other race” category. Folic acid intake in the periconceptional period, defined as the month 
prior to and after the last menstrual period (LMP), was determined through the information 
collected on vitamin and supplement use (1976+) and responses to a food frequency 
questionnaire on natural sources (e.g., spinach) and fortified products (e.g., pasta) (1988+) 
[Willett et al., 1985]. Folic acid intake was based only on reported consumption of vitamins/
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supplements prior to 1988 because information on dietary sources was unavailable and the 
contribution from diet during this period would have been small since fortification had yet to 
occur. Subsequently, folic acid intake was based on the combination of sources from 
vitamins/supplements and diet. Subjects were categorized into two groups; those achieving 
the recommended amount of ≥400 μg/day of folic acid (“high intake”) and those with an 
intake of <400 μg/day (“low intake”). Food folate was discounted by 30% due to lower 
bioavailability. Methods to determine folic acid intake from diet and supplements in the 
BDS have previously been described in detail [Yazdy et al., 2012].
STATISTICAL ANALYSIS
Frequencies and percentages of demographic characteristics were calculated for isolated 
cases, non-isolated cases overall, and subgroups of non-isolated cases. Demographic 
characteristics included maternal race/ethnicity (non-Hispanic white, non-Hispanic black, 
Hispanic [1983+], other), age at conception (<20, 20–29, ≥30 years), education (<12, 12, 
>12 years), infant sex, and study center, along with folic acid intake in the periconceptional 
period. To assess changes in types of cases over time, the distribution of case types between 
pre- and post-fortification periods were compared. The pre-fortification period included 
mothers of cases with an LMP prior to January 1, 1996. The post-fortification period was 
defined as those with an LMP date on or after January 1, 1998. Cases with an LMP date 
from 1996 to 1997 were excluded since this was a transitional period in which fortification 
of the food supply began, but was not yet mandated. Analyses were performed using SAS 
9.3 software.
RESULTS
A total of 1,237 cases of SB were ascertained by the BDS from 1976 to 2011. After 
exclusion of cases with chromosomal anomalies, recognized syndromes, amniotic bands, 
body wall defects, conjoined twins, and unconfirmed cases, 1,170 cases were included in 
this analysis (Fig. 1). Of these, 80.4% were classified as isolated, 19.1% were classified as 
non-isolated, and 0.5% of cases were unknown.
The 223 non-isolated cases were further divided into the following subgroups based on 
accompanying major defects; midline defects (n= 146), renal defects (n = 42), genital 
defects (n = 34), heart defects (n = 34), and laterality defects (n = 5). Among midline 
defects, present in 65% of non-isolated cases, brain reduction defects were most common, 
followed by imperforate anus, cloacal exstrophy, omphalocele, and bladder exstrophy (Table 
I). OEIS complex, which includes all the following defects; omphalocele, exstrophy of the 
bladder, imperforate anus, and SB [Carey et al., 1978], was observed among four cases. 
Renal defects were present in 19% of non-isolated cases; the most common defects included 
unilateral kidney absence/agenesis and horseshoe kidney (14 and 7 cases, respectively). The 
genital defect group (15%) was largely comprised of undescended testicle at >37 weeks’ 
gestation and ambiguous genitalia. Among congenital heart defects, (15%), ventricular 
septal defects were most common, followed by double outlet right ventricle. Laterality 
defects were observed in only five cases (2%), and thus their epidemiologic characteristics 
were not tabulated.
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Descriptive characteristics of isolated cases and non-isolated cases and their subgroups are 
presented in Table II. In all, mothers were more likely to be white, non-Hispanic and 20–29 
years old at conception. However, compared to all other groups, cases with genital defects or 
heart defects had greater proportions of mothers aged less than 20 years and with less than 
12 years of education. Cases with heart defects had the highest proportion of mothers whose 
race was either Hispanic or “other” (17.6% and 29.4%, respectively). Female predominance 
was evident in all case subgroups with the exception of midline and genital defects, both of 
which include hypospadias, a defect occurring only among males. Cases with renal defects 
had the highest proportion of females (61.9%).
Folic acid intake was similar between isolated and non-isolated cases, with at least 70% not 
achieving the current recommendation of ≥400 μg. Renal and heart defect subgroups had the 
highest proportion of mothers with <400 μg of daily folic acid (78.6% and 76.5%, 
respectively). Sufficient data to categorize folic acid intake were lacking in 2.4–5.9% of 
each defect grouping.
As expected, the proportion of women with intake of at least 400 μg of folic acid was higher 
in the post-fortification period. Following mandated folic acid fortification of the foods in 
1998, the percentage of case mothers achieving a folic acid intake ≥400 μg increased from 
17.5% to 49.4%. During those periods, the proportion of isolated cases decreased from 83% 
to 72% (Table III).
The demographic characteristics among isolated and nonisolated cases also changed from 
pre- to post-fortification periods. In the pre-fortification time period, mothers of isolated 
cases were less likely to be black, <20 years old, or have <12 years of education compared 
to non-isolated cases, whereas the opposite was observed in the post-fortification period 
(Table IV). The female predominance was most apparent in pre-fortification isolated cases. 
Despite changing demographics, in both periods, mothers of non-isolated cases were less 
likely to achieve a folic acid intake ≥400 μg. Characteristics of non-isolated sub-groups in 
pre- and post-fortification periods are presented in Table V. The heart subgroup had the 
highest proportion of mothers not achieving the recommended amount of folic acid in both 
the pre- and post-fortification periods.
DISCUSSION
This large sample of SB cases with detailed medical record information and maternal 
interview data, permitted description of the epidemiologic characteristics of SB cases with 
and without accompanying malformations. Approximately one-fifth of all SB cases in the 
present study were accompanied by other major malformations, a proportion similar to the 
20.2% reported among a hospital-based population in France from 1979 through 2008 [Stoll 
et al., 2011] and the 21.0% reported in the population-based Metropolitan Atlanta 
Congenital Defects Program from 1968 to 1979 [Khoury et al., 1982]. A much lower rate of 
non-isolated SB (12%) was reported from the South Carolina Birth Defects Surveillance 
Program (1992–2002), which might be due to under-ascertainment of accompanying 
malformations in the large number of cases that were identified by prenatal screening 
[Stevenson et al., 2004].
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In the present study, the most common subgroup of accompanying defects was midline 
defects, which were present in 65% of non-isolated cases. Previous studies focusing on all 
types of NTDs reported midline defects among 41–48% of all non-isolated NTDs 
[Stevenson et al., 2000; Stoll et al., 2011]. The concept of a primary midline developmental 
field was first introduced by Opitz and Gilbert [1982] who postulated that insults during 
early blastogenesis would affect the whole embryo and produce associated defects of 
blastogenic origin [Martinez-Frias, 1995]. Among our cases, brain reduction defects, such as 
agenesis of the corpus callosum and holoproscencephaly, constituted the majority of midline 
defects. Development of midline brain structures, including the corpus callosum, is known 
to be compromised in embryos affected by SB [Juranek and Salman, 2010] and may 
therefore be secondary to SB. However, after exclusion of brain reduction defects from the 
midline category, the midline subgroup was still the largest, with 76 cases, or 34% of all 
non-isolated cases. It has been suggested that other midline defects, such as omphalocele, 
may in fact be secondary to SB [Calzolari et al., 1997]. In the event that some of these cases 
are truly isolated, misclassification would be introduced by including them in the midline 
sub-grouping. Other large subgroups of accompanying defects were renal, genital, and heart 
defects. This is the first study that describes epidemiologic characteristics of not only 
isolated and non-isolated SB cases, but also these large subgroups of defects co-occurring 
with SB.
The consistently observed female predominance of SB [Shaw et al., 2003] was evident in 
isolated cases, but not in non-isolated cases overall. This predominance diminished in the 
post-fortification period. In the pre-fortification era, Stevenson et al. [2000] also observed a 
female predominance in isolated, but not non-isolated, cases of SB. The renal defect 
subgroup had the greatest proportion of females (62%). There is no clear explanation for this 
observation given that renal defects are not known to occur more frequently in female 
offspring [Shaw et al., 2003; Rittler et al., 2004]. Unilateral renal agenesis can be 
asymptomatic and while the presence of SB may have prompted the diagnosis, such 
diagnostic bias would not explain the female predominance. The genital defect group 
showed a male predominance which was driven by the inclusion of cases of undescended 
testicles at >37 weeks gestation and hypospadias, birth defects occurring only in males.
Differences in socio-demographic factors and folic acid intake were observed for various 
phenotypic subgroups, suggesting possible etiologic heterogeneity. Specifically, while 
relatively little differences in maternal race/ethnicity, age, education, and folic acid intake 
were observed for SB cases occurring alone compared to those accompanied by other major 
malformations overall, for cases with a genital or heart defect, mothers were younger and 
less educated than other case subgroups. Cases with SB and a heart defect were also more 
likely to be Hispanic and least likely to ingest ≥400 μg of folic acid daily. Lower 
socioeconomic status is correlated with lower folic acid intake [Centers for Disease Control 
and Prevention, 1999; Carmichael et al., 2006] and many other nutritional and behavioral 
factors, raising the possibility that our observations could be explained by any number of 
such correlated exposures. However, when the effects of folic acid intake and indicators of 
socioeconomic status(maternal race/ethnicity, age, or education) were considered 
simultaneously, the proportion of heart defect cases remained greater among those with folic 
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acid intake <400 μg/day (data not shown). We were unable to assess known risk factors for 
SB such as pre-gestational diabetes and valproate exposure due to small numbers.
Folic acid fortification was associated with a decrease in the proportion of isolated cases and 
thereby an increase in the proportion of non-isolated cases. The higher proportion of non-
isolated SB cases overall after fortification is consistent with previous reports, indicating 
that folic acid is most effective in reducing the occurrence of isolated SB [Stevenson et al., 
2004;Lopez-Camelo et al., 2010]. This finding was most striking for SB cases with heart 
defects. If folic acid intake of <400 μg/day is more strongly associated with SB when it 
occurs with a heart defect, then we might expect there to be more such cases during the pre-
fortification years. However, we observed the opposite pattern, with a higher proportion of 
heart defects in the post-fortification years. Explanations for this observation include 
improved ascertainment of heart defects relative to the other defect categories or the role of 
folic acid in reducing the other defect sub-groups disproportionately to the heart defect 
group. Thus, this study provides new evidence that folic acid may be more effective in 
reducing the occurrence of particular subgroups of non-isolated SB.
A study by De Wals et al. [2008] observed that the transition from pre-to post-fortification 
in Canada was associated with a reduction in upper SB, defined as cranial, cervical, and 
thoracic lesions, but not lower SB, defined as lumbar and sacral lesions. Information on 
lesion was not available for all subjects in the present analysis, but a sub-analysis similarly 
showed a decline in upper SB, but not lower SB. The decline in upper SB occurred in both 
isolated and non-isolated SB, but was larger for non-isolated SB (data not shown).
The cases in this descriptive analysis are part of a larger case–control study that was 
designed to study potential risk factors for a spectrum of birth defects, therefore, the 
prevalence of SB cannot be estimated. A challenge in studying NTDs is the ascertainment of 
electively terminated cases. Though terminated cases were included in this study, they were 
not routinely collected. Compared to previous studies which found that elective terminations 
accounted for 35–44% of SB cases [Stevenson et al., 2000; Cragan and Gilboa, 2009], 
18.2% of SB cases included in this study were electively terminated, that proportion was 
11.3% in another large multi-site case–control study of birth defects in the United States 
[Agopian et al., 2012]. A previous study reported that terminated fetuses with SB were more 
likely to have body wall defects, diaphragmatic hernia, and cystic kidney compared to their 
liveborn counterparts [Kalien et al., 1998], and a recent meta-analysis showed that the 
frequency of termination for all cases was higher than for isolated cases alone [Johnson et 
al., 2012]. Thus, it is likely that our study underestimated the proportion of non-isolated 
defects due to incomplete ascertainment of terminations. However, ascertainment of 
terminations was higher during the pre-fortification period, 19.5% compared to 15.7% in the 
post-fortification period, and would not explain the greater proportion of non-isolated cases 
during the post-fortification period.
The present study supports previous findings that folic acid is more effective in reducing the 
occurrence of isolated SB compared to non-isolated SB; this effect was observed in both the 
pre- and post-fortification periods, and was most striking for heart defects. Further, our 
study extends previous findings in highlighting the importance of distinguishing between 
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isolated and non-isolated cases in the etiologic research of SB. Differentiating non-isolated 
cases of SB into groupings based on their accompanying defects may provide clearer 
insights into their underlying etiology.
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TABLE III
Distribution of Spina Bifida Case Types, Pre- and Post-Fortification
Pre-fortificationa (n=880) Post-fortificationb (n =256)
n % n %
Isolated 733 83.3 185 72.3
Non-isolated 147 16.7   71 27.7
 Midline 100 68.0   44 62.0
 Renal   32 21.8     9 12.7
 Genital   22 15.0   12 16.9
 Heart   17 11.6   16 22.5
a
LMP dates prior to January 1, 1996.
b
LMP dates on or after January 1, 1998.
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Am J Med Genet A. Author manuscript; available in PMC 2015 March 09.
